当前位置: 首页 >> 检索结果
6862. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain.
作者: Ehud Rinott.;Ilan Youngster.;Anat Yaskolka Meir.;Gal Tsaban.;Hila Zelicha.;Alon Kaplan.;Dan Knights.;Kieran Tuohy.;Francesca Fava.;Matthias Uwe Scholz.;Oren Ziv.;Elad Rubin.;Amir Tirosh.;Assaf Rudich.;Matthias Blüher.;Michael Stumvoll.;Uta Ceglarek.;Karine Clement.;Omry Koren.;Dong D Wang.;Frank B Hu.;Meir J Stampfer.;Iris Shai.
来源: Gastroenterology. 2021年160卷1期158-173.e10页
We evaluated the efficacy and safety of diet-modulated autologous fecal microbiota transplantation (aFMT) for treatment of weight regain after the weight-loss phase.
6869. Transcription and DNA Methylation Patterns of Blood-Derived CD8+ T Cells Are Associated With Age and Inflammatory Bowel Disease But Do Not Predict Prognosis.
作者: Marco Gasparetto.;Felicity Payne.;Komal Nayak.;Judith Kraiczy.;Claire Glemas.;Yosef Philip-McKenzie.;Alexander Ross.;Rachel D Edgar.;Daniel R Zerbino.;Camilla Salvestrini.;Franco Torrente.;Nicholas T Ventham.;Rahul Kalla.;Jack Satsangi.;Peter Sarkies.;Robert Heuschkel.;Matthias Zilbauer.
来源: Gastroenterology. 2021年160卷1期232-244.e7页
Gene expression patterns of CD8+ T cells have been reported to correlate with clinical outcomes of adults with inflammatory bowel diseases (IBD). We aimed to validate these findings in independent patient cohorts.
6871. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
作者: Stephen A Harrison.;Guy Neff.;Cynthia D Guy.;Mustafa R Bashir.;Angelo H Paredes.;Juan P Frias.;Ziad Younes.;James F Trotter.;Nadege T Gunn.;Sam E Moussa.;Anita Kohli.;Kristin Nelson.;Mildred Gottwald.;William C G Chang.;Andrew Z Yan.;Alex M DePaoli.;Lei Ling.;Hsiao D Lieu.
来源: Gastroenterology. 2021年160卷1期219-231.e1页
Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepatitis (NASH).
6879. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
作者: Matthew R Henn.;Edward J O'Brien.;Liyang Diao.;Brian G Feagan.;William J Sandborn.;Curtis Huttenhower.;Jennifer R Wortman.;Barbara H McGovern.;Sherry Wang-Weigand.;David I Lichter.;Meghan Chafee.;Christopher B Ford.;Patricia Bernardo.;Peng Zhao.;Sheri Simmons.;Amelia D Tomlinson.;David N Cook.;Roger J Pomerantz.;Bharat K Misra.;John G Auninš.;Michele Trucksis.
来源: Gastroenterology. 2021年160卷1期115-127.e30页
Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon.
6880. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
作者: Leonardo L Lardi.;Rodrigo M Lul.;Gabriela Z Port.;Gabriela P Coral.;Alessandra Peres.;Gilson P Dornelles.;Fernanda Branco.;Sabrina Fernandes.;Carolina G Leães.;Angelo A Mattos.;Caroline Buss.;Cristiane V Tovo.
来源: Minerva Gastroenterol (Torino). 2022年68卷1期85-90页
To evaluate the performance of a non-invasive test (Fibromax™, Ferring Pharmaceutical, Saint-Prex, Switzerland) and inflamatory markers (IL-1β, IL-6, IL-8, TNF-α, MCP-1) in the diagnosis and staging of patients with non-alcoholic fatty liver disease.
|